Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
Status: Enrolling
Updated:  2/14/2017
Clinical Research Facility
mi
from
The Woodlands, TX
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
Status: Enrolling
Updated: 2/14/2017
Clinical Research Facility
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
Status: Enrolling
Updated:  2/14/2017
Clinical Research Facility
mi
from
Orem, UT
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
Status: Enrolling
Updated: 2/14/2017
Clinical Research Facility
mi
from
Orem, UT
Click here to add this to my saved trials
Nicotinic Receptors and Schizophrenia
Nicotinic Receptors and Schizophrenia: Phase II
Status: Enrolling
Updated:  2/28/2017
UColorado Denver
mi
from
Aurora, CO
Nicotinic Receptors and Schizophrenia
Nicotinic Receptors and Schizophrenia: Phase II
Status: Enrolling
Updated: 2/28/2017
UColorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Nicotinic Receptors and Schizophrenia
Nicotinic Receptors and Schizophrenia: Phase II
Status: Enrolling
Updated:  2/28/2017
University of Colorado-Anschutz Medical Campus, Department of Psychiatry
mi
from
Aurora, CO
Nicotinic Receptors and Schizophrenia
Nicotinic Receptors and Schizophrenia: Phase II
Status: Enrolling
Updated: 2/28/2017
University of Colorado-Anschutz Medical Campus, Department of Psychiatry
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Long Beach, CA
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Trial to Assess the Antipsychotic Efficacy of ITI-007
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia
Status: Enrolling
Updated:  3/9/2017
Clinical Site
mi
from
Long Beach, CA
A Trial to Assess the Antipsychotic Efficacy of ITI-007
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia
Status: Enrolling
Updated: 3/9/2017
Clinical Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia
An Open-Label Positron Emission Tomography (PET) Study to Demonstrate Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of ITI-007 in Stable Schizophrenia Patients
Status: Enrolling
Updated:  3/9/2017
Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia
An Open-Label Positron Emission Tomography (PET) Study to Demonstrate Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of ITI-007 in Stable Schizophrenia Patients
Status: Enrolling
Updated: 3/9/2017
Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
Status: Enrolling
Updated:  3/13/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
Status: Enrolling
Updated: 3/13/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
Status: Enrolling
Updated:  3/13/2017
Hassman Research Institute
mi
from
Berlin, NJ
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
Status: Enrolling
Updated: 3/13/2017
Hassman Research Institute
mi
from
Berlin, NJ
Click here to add this to my saved trials
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
Status: Enrolling
Updated:  3/13/2017
KHM Hospital
mi
from
Chennai,
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
Status: Enrolling
Updated: 3/13/2017
KHM Hospital
mi
from
Chennai,
Click here to add this to my saved trials
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated:  3/22/2017
Henderson Mental Health Center
mi
from
Ft Lauderdale, FL
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated: 3/22/2017
Henderson Mental Health Center
mi
from
Ft Lauderdale, FL
Click here to add this to my saved trials
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated:  3/22/2017
Community Mental Health Center, Inc.
mi
from
Lawrenceburg, IN
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated: 3/22/2017
Community Mental Health Center, Inc.
mi
from
Lawrenceburg, IN
Click here to add this to my saved trials
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated:  3/22/2017
Cherry Street
mi
from
Grand Rapids, MI
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated: 3/22/2017
Cherry Street
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated:  3/22/2017
UMKC School of Pharmacy
mi
from
Kansas City, MO
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated: 3/22/2017
UMKC School of Pharmacy
mi
from
Kansas City, MO
Click here to add this to my saved trials
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated:  3/22/2017
Burrell Behavioral Health
mi
from
Springfield, MO
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated: 3/22/2017
Burrell Behavioral Health
mi
from
Springfield, MO
Click here to add this to my saved trials
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated:  3/22/2017
Mental Health Center of Greater Manchester
mi
from
Manchester, NH
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated: 3/22/2017
Mental Health Center of Greater Manchester
mi
from
Manchester, NH
Click here to add this to my saved trials
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated:  3/22/2017
University of New Mexico Department of Psychiatry UNM Health Sciences Center
mi
from
Albuquerque, NM
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated: 3/22/2017
University of New Mexico Department of Psychiatry UNM Health Sciences Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated:  3/22/2017
PeaceHealth Oregon/Lane County Behavioral Health Services
mi
from
Eugene, OR
Improving Care and Reducing Cost Study
The Improving Care and Reducing Cost (ICRC) Program
Status: Enrolling
Updated: 3/22/2017
PeaceHealth Oregon/Lane County Behavioral Health Services
mi
from
Eugene, OR
Click here to add this to my saved trials
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
A Phase I, Double-Blind, Randomized, Multiple-Dose, Pilot Study Comparing Xanomeline Administered Alone to Xanomeline Administered in Combination With Trospium Chloride in Normal Healthy Volunteers
Status: Enrolling
Updated:  4/18/2017
Medpace
mi
from
Cincinnati, OH
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
A Phase I, Double-Blind, Randomized, Multiple-Dose, Pilot Study Comparing Xanomeline Administered Alone to Xanomeline Administered in Combination With Trospium Chloride in Normal Healthy Volunteers
Status: Enrolling
Updated: 4/18/2017
Medpace
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effects of Modafinil on Brain Function in Patients With Schizophrenia
Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Modafinil on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype
Status: Enrolling
Updated:  4/20/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Effects of Modafinil on Brain Function in Patients With Schizophrenia
Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Modafinil on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype
Status: Enrolling
Updated: 4/20/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia
Brain Blood Flow Changes Elicited by Oxytocin in Healthy and Schizophrenic Volunteers, an Assessment Using Positron Emission Tomography and 15-Oxygen Labeled Water
Status: Enrolling
Updated:  4/20/2017
Maryland Psychiatric Research Center
mi
from
Catonsville, MD
Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia
Brain Blood Flow Changes Elicited by Oxytocin in Healthy and Schizophrenic Volunteers, an Assessment Using Positron Emission Tomography and 15-Oxygen Labeled Water
Status: Enrolling
Updated: 4/20/2017
Maryland Psychiatric Research Center
mi
from
Catonsville, MD
Click here to add this to my saved trials
Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
Behavioral Treatment of Drug Abuse in SPMI Patients
Status: Enrolling
Updated:  4/20/2017
Health Care for the Homeless
mi
from
Baltimore, MD
Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
Behavioral Treatment of Drug Abuse in SPMI Patients
Status: Enrolling
Updated: 4/20/2017
Health Care for the Homeless
mi
from
Baltimore, MD
Click here to add this to my saved trials
Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
Behavioral Treatment of Drug Abuse in SPMI Patients
Status: Enrolling
Updated:  4/20/2017
University of Maryland, Baltimore
mi
from
Baltimore, MD
Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
Behavioral Treatment of Drug Abuse in SPMI Patients
Status: Enrolling
Updated: 4/20/2017
University of Maryland, Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
Behavioral Treatment of Drug Abuse in SPMI Patients
Status: Enrolling
Updated:  4/20/2017
VA Maryland Health Care System
mi
from
Baltimore, MD
Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
Behavioral Treatment of Drug Abuse in SPMI Patients
Status: Enrolling
Updated: 4/20/2017
VA Maryland Health Care System
mi
from
Baltimore, MD
Click here to add this to my saved trials
Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
Behavioral Treatment of Drug Abuse in SPMI Patients
Status: Enrolling
Updated:  4/20/2017
Mosaic Community Services
mi
from
Catonsville, MD
Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
Behavioral Treatment of Drug Abuse in SPMI Patients
Status: Enrolling
Updated: 4/20/2017
Mosaic Community Services
mi
from
Catonsville, MD
Click here to add this to my saved trials
Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis
Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis
Status: Enrolling
Updated:  4/24/2017
University of Arizona
mi
from
Tucson, AZ
Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis
Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis
Status: Enrolling
Updated: 4/24/2017
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
Status: Enrolling
Updated:  4/24/2017
University of Arizona Department of Psychiatry
mi
from
Tucson, AZ
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
Status: Enrolling
Updated: 4/24/2017
University of Arizona Department of Psychiatry
mi
from
Tucson, AZ
Click here to add this to my saved trials
Social Cognition in Longstanding Psychosis
Social Cognition in Longstanding Psychosis
Status: Enrolling
Updated:  4/24/2017
University of Arizona Department of Psychiatry
mi
from
Tucson, AZ
Social Cognition in Longstanding Psychosis
Social Cognition in Longstanding Psychosis
Status: Enrolling
Updated: 4/24/2017
University of Arizona Department of Psychiatry
mi
from
Tucson, AZ
Click here to add this to my saved trials
Cognitive-Behavioral Therapy in Veterans With Schizophrenia
Cognitive-Behavioral Therapy in Veterans With Schizophrenia
Status: Enrolling
Updated:  5/9/2017
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Cognitive-Behavioral Therapy in Veterans With Schizophrenia
Cognitive-Behavioral Therapy in Veterans With Schizophrenia
Status: Enrolling
Updated: 5/9/2017
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Click here to add this to my saved trials
Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine
Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine
Status: Enrolling
Updated:  5/11/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine
Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine
Status: Enrolling
Updated: 5/11/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Staccato Loxapine in Agitation (Proof of Concept)
A Multi-center, Randomized, Double-blind, Placebo-controlled, Single Dose Efficacy and Safety Study of StaccatoTM Loxapine for Inhalation in Schizophrenic Patients With Agitation.
Status: Enrolling
Updated:  5/30/2017
Pacific Clinical Research Medical Group, 1317 West Foothill Blvd, Suite 200
mi
from
Upland, CA
Staccato Loxapine in Agitation (Proof of Concept)
A Multi-center, Randomized, Double-blind, Placebo-controlled, Single Dose Efficacy and Safety Study of StaccatoTM Loxapine for Inhalation in Schizophrenic Patients With Agitation.
Status: Enrolling
Updated: 5/30/2017
Pacific Clinical Research Medical Group, 1317 West Foothill Blvd, Suite 200
mi
from
Upland, CA
Click here to add this to my saved trials
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
Status: Enrolling
Updated:  6/6/2017
CNS Network
mi
from
Garden Grove, CA
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
Status: Enrolling
Updated: 6/6/2017
CNS Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
Status: Enrolling
Updated:  6/6/2017
Parexel California Clinical Trials Medical Group
mi
from
Glendale, CA
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
Status: Enrolling
Updated: 6/6/2017
Parexel California Clinical Trials Medical Group
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
Status: Enrolling
Updated:  6/6/2017
St. Louis Clinical Trials, LLC
mi
from
Saint Louis, MO
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
Status: Enrolling
Updated: 6/6/2017
St. Louis Clinical Trials, LLC
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated:  6/20/2017
Massachusetts General Hospital
mi
from
Boston, MA
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated: 6/20/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated:  6/20/2017
Rutgers University-Robert Wood Johnson Medical School
mi
from
Piscataway, NJ
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated: 6/20/2017
Rutgers University-Robert Wood Johnson Medical School
mi
from
Piscataway, NJ
Click here to add this to my saved trials
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated:  6/20/2017
Sheppard Pratt Health System
mi
from
Baltimore, MD
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated: 6/20/2017
Sheppard Pratt Health System
mi
from
Baltimore, MD
Click here to add this to my saved trials
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated:  6/20/2017
Richmond Behavior Associates
mi
from
Staten Island, NY
Schizophrenia Cognition Scale Development
Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
Status: Enrolling
Updated: 6/20/2017
Richmond Behavior Associates
mi
from
Staten Island, NY
Click here to add this to my saved trials
Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia
The Use of Daily, Intranasal Oxytocin for the Treatment of Childhood-Onset Schizophrenia (COS), a Randomized Double-Blind Trial
Status: Enrolling
Updated:  7/6/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia
The Use of Daily, Intranasal Oxytocin for the Treatment of Childhood-Onset Schizophrenia (COS), a Randomized Double-Blind Trial
Status: Enrolling
Updated: 7/6/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Biomarkers in First Episode Schizophrenia
Biomarkers in First Episode Schizophrenia
Status: Enrolling
Updated:  7/12/2017
Bellevue Hospital
mi
from
New York, NY
Biomarkers in First Episode Schizophrenia
Biomarkers in First Episode Schizophrenia
Status: Enrolling
Updated: 7/12/2017
Bellevue Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
Status: Enrolling
Updated:  8/7/2017
Maryland Psychiatric Research Center (MPRC)
mi
from
Catonsville, MD
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
Status: Enrolling
Updated: 8/7/2017
Maryland Psychiatric Research Center (MPRC)
mi
from
Catonsville, MD
Click here to add this to my saved trials
Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Status: Enrolling
Updated:  8/31/2017
University of California, Los Angeles, School of Medicine
mi
from
Los Angeles, CA
Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Status: Enrolling
Updated: 8/31/2017
University of California, Los Angeles, School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Modafinil Effects on Cognition in Schizophrenia Patients
A Dose-response Study of Modafinil Effects on Cognition in Schizophrenia Patients.
Status: Enrolling
Updated:  8/31/2017
University of California Davis School of Medicine
mi
from
Sacramento, CA
Modafinil Effects on Cognition in Schizophrenia Patients
A Dose-response Study of Modafinil Effects on Cognition in Schizophrenia Patients.
Status: Enrolling
Updated: 8/31/2017
University of California Davis School of Medicine
mi
from
Sacramento, CA
Click here to add this to my saved trials
Modafinil Effects on Cognition in Schizophrenia Patients
A Dose-response Study of Modafinil Effects on Cognition in Schizophrenia Patients.
Status: Enrolling
Updated:  8/31/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Modafinil Effects on Cognition in Schizophrenia Patients
A Dose-response Study of Modafinil Effects on Cognition in Schizophrenia Patients.
Status: Enrolling
Updated: 8/31/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Springdale, AK
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Springdale, AK
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Culver City, CA
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Culver City, CA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Lemon Grove, CA
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Lemon Grove, CA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Long Beach, CA
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Pico Rivera, CA
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Pico Rivera, CA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated:  9/3/2017
Clinical Research Facility
mi
from
Lauderhill, FL
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Status: Enrolling
Updated: 9/3/2017
Clinical Research Facility
mi
from
Lauderhill, FL
Click here to add this to my saved trials